Laboratory Diagnosis and Management of von Willebrand Disease in South Africa

ABSTRACT

Patients with von Willebrand disease (VWD) in South Africa are cared for in 17 Hemophilia Treatment Centers. The exact prevalence of the disease is uncertain, but 539 patients are annotated in registries. VWD patients are mostly diagnosed in the five largest academic centers, and the classification of the subtypes is performed by one of these, the VWD testing facility. An algorithm is used for the diagnosis of VWD. The distribution of subtypes diagnosed by the VWD reference center is 38%, 58%, and 4% for type 1, 2, and 3, respectively, and ~15% of plasma samples received are rejected due to poor storage and transport conditions. A novel single nucleotide polymorphism has been found in an African patient with type 2B VWD. From the type 1 VWD patients who were diagnosed by the VWD testing facility, 45% seem to have an increased VWF clearance phenotype with a propeptide-to-antigen ratio of 1.9 ± 0.3. VWD patients are treated with desmopressin, factor (F)VIII/VWF concentrate (Haemosolvate FVIII; National Bioproducts Institute, Durban, South Africa), and tranexamic acid. Haemosolvate FVIII contains a VWF antigen concentration of 167 ± 27 IU/mL, a ristocetin cofactor activity of 100 ± 29 IU/mL, a collagen binding activity of 99 ± 29 IU/mL, normal VWF multimers, and a FVIII concentration of 50 IU/mL. Not all patients with VWD are currently classified, and many VWD patients in South Africa are probably undiagnosed.

von Willebrand disease - classification - diagnosis - hemophilia treatment centers - South Africa

REFERENCES

• 1 Mahlangu JN. Medical and Scientific Council of the South African Haemophilia Foundation . Haemophilia care in South Africa: 2004–2007 look back.  Haemophilia. 2009;  15 (1) 135-141
• 2 Karabus C. Reports on the South African Haemophilia Registry. Paper presented at: Annual meeting of the Medical and Scientific Advisory Council of the South African Haemophilia Foundation; Johannesburg, South Africa; 2010
• 3 Coetzee MJ, Coetzee M, Jooste P, Goga Y. The Web-based Registry of the South African Haemophilia Foundation. Available at: http://www.hemophilia.org.za/registry Accessed January 25, 2011
• 4 Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Centers (AICE) . Guidelines for the diagnosis and management of von Willebrand disease in Italy.  Haemophilia. 2002;  8 (5) 607-621
• 5 Meiring SM, Kelderman M, Badenhorst PN. Laboratory diagnosis of von Willebrand disease.  European Haematology. 2009;  3 (1) 33-36
• 6 Favaloro EJ, Mehrabani PA. Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results.  Haemophilia. 1996;  2 218-223
• 7 Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel . Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey.  Thromb Haemost. 1999;  82 (4) 1276-1282